1. Home
  2. HEQ vs SLGL Comparison

HEQ vs SLGL Comparison

Compare HEQ & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Hancock Hedged Equity & Income Fund of Beneficial Interest

HEQ

John Hancock Hedged Equity & Income Fund of Beneficial Interest

HOLD

Current Price

$11.53

Market Cap

134.7M

Sector

Finance

ML Signal

HOLD

Logo Sol-Gel Technologies Ltd.

SLGL

Sol-Gel Technologies Ltd.

HOLD

Current Price

$87.63

Market Cap

159.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HEQ
SLGL
Founded
N/A
1997
Country
United States
Israel
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.7M
159.7M
IPO Year
2010
2016

Fundamental Metrics

Financial Performance
Metric
HEQ
SLGL
Price
$11.53
$87.63
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$110.00
AVG Volume (30 Days)
45.7K
13.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$122.71
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.23
$0.40
52 Week High
$11.55
$85.60

Technical Indicators

Market Signals
Indicator
HEQ
SLGL
Relative Strength Index (RSI) 76.52 N/A
Support Level $10.55 N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.08 0.00
MACD 0.02 0.00
Stochastic Oscillator 100.00 0.00

Price Performance

Historical Comparison
HEQ
SLGL

About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest

John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

Share on Social Networks: